DEVELOPING NEW GSC-DERIVED XENOGRAFT MODELS AND ANALYZING HOW IT COMPARES WITH GLIOBLASTOMA TUMOR PROLIFERATION
DOI:
https://doi.org/10.58445/rars.1008Keywords:
glioblastoma, gsc-derived xenograft, glioma stem cellsAbstract
The purpose of this research is to investigate the proliferative rate of patient-derived glioma stem cells (GSCs) and glioma cell lines in comparison with glioblastoma (GBM) tumors to elucidate the dynamics of glioma progression. Utilizing a comprehensive experimental design, patient-derived GSCs were successfully shown to form tumors in immunocompromised mice and could be passaged serially, highlighting their potent tumor-initiating and self-renewal capabilities. The average Ki-67 proliferative index, a key marker of cellular proliferation, was determined to be 37.63%, signifying a substantial level of cellular activity within the GSCs. Distinct proliferative profiles were observed among GSCs, glioma cell lines, and GBM tumors, with GSCs exhibiting a significantly higher proliferation rate. This supports the hypothesis that GSCs contribute significantly to the aggressive nature of glioma progression. The research contributes valuable insights into glioma biology, emphasizing the heterogeneous nature of gliomas and underscoring the potential role of GSCs as key drivers of glioma growth. The experimental design, including xenograft tumor formation, serial passaging, and molecular analyses, provided a robust foundation for understanding the complex interplay of proliferative mechanisms within gliomas. Replication and validation steps with multiple GSC samples and different glioma cell lines enhanced the reliability of the findings. Overall, this study enhances our understanding of glioma biology and may guide the development of targeted therapeutic strategies for improved clinical outcomes.
References
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., ... & Mirimanoff, R. O. (2009). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996.
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., ... & Wesseling, P. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6), 803-820.
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203-1217.
Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual Review of Medicine, 53(1), 615-627.
Wen, P. Y., & Kesari, S. (2008). Malignant gliomas in adults. New England Journal of Medicine, 359(5), 492-507.
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., ... & Suva, M. L. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190), 1396-1401.
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2011). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138(4), 645-659.
Additional Files
Posted
Categories
License
Copyright (c) 2024 Sujay Nalla
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.